DIG
TCRX icon

Dauntless Investment Group’s TScan Therapeutics TCRX Stock Holding History

Dauntless Investment Group’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-110,345
Closed -$335K – 86
2024
Q4 		$335K Buy
+110,345
New +$500K 0.35% 45

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Dauntless Investment Group's TCRX Position: Q1 2025 in Review

Dauntless Investment Group sold out of TScan Therapeutics (TCRX) in Q1 2025, closing a stake of 110,345 shares — an estimated $335K sold.

Dauntless Investment Group first reported a position in TCRX in Q4 2024 and held it in 1 quarter. The position peaked at $335K in Q4 2024. 92 funds tracked by Wall St. Rank hold TCRX as of Q1 2025.

  • Dauntless Investment Group reported no remaining TScan Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Dauntless Investment Group sold 110,345 TScan Therapeutics shares in Q1 2025, an estimated $335K.
  • Dauntless Investment Group first reported a position in TScan Therapeutics in Q4 2024 and held it in 1 quarter.
  • Dauntless Investment Group's TScan Therapeutics position peaked at $335K in Q4 2024.
  • 92 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2025.

Based on Dauntless Investment Group's 13F filing for Q1 2025, filed 7 May 2025.